DIM
SPRO icon

DLK Investment Management’s Spero Therapeutics SPRO Stock Holding History

DLK Investment Management’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$40.8K Buy
+31,355
New +$82K 0.02% 90
2025
Q2 		– Sell
-29,825
Closed -$21.5K – 100
2025
Q1 		$21.5K Buy
29,825
+870
+3% +$734 0.01% 83
2024
Q4 		$29.8K Sell
28,955
-2,400
-8% -$2.85K 0.01% 83
2024
Q3 		$42K Hold
31,355
– – 0.02% 100
2024
Q2 		$40.8K Hold
31,355
– – 0.02% 95
2024
Q1 		$53.9K Hold
31,355
– – 0.02% 91
2023
Q4 		$46.1K Buy
+31,355
New +$37.4K 0.02% 89

Other funds holding SPRO

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

DLK Investment Management's SPRO Position: Q2 2026 in Review

DLK Investment Management opened a new position in Spero Therapeutics (SPRO) in Q2 2026: 31,355 shares worth $40.8K. The stake represents 0.02% of the portfolio and ranks #90 among its holdings. This is a return to the name: DLK Investment Management previously reported a position in SPRO as recently as Q1 2025.

DLK Investment Management first reported a position in SPRO in Q4 2023 and has held it in 7 quarters since. The position peaked at $53.9K in Q1 2024. 4 funds tracked by Wall St. Rank hold SPRO as of Q2 2026.

  • DLK Investment Management held 31,355 shares of Spero Therapeutics worth $40.8K as of Q2 2026.
  • Spero Therapeutics was a new DLK Investment Management position in Q2 2026.
  • Spero Therapeutics made up 0.02% of DLK Investment Management's portfolio in Q2 2026, its #90 holding.
  • DLK Investment Management first reported a position in Spero Therapeutics in Q4 2023 and has held it in 7 quarters since.
  • DLK Investment Management's Spero Therapeutics position peaked at $53.9K in Q1 2024.
  • 4 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2026.

Based on DLK Investment Management's 13F filing for Q2 2026, filed 14 Jul 2026.